Jerrod Denham

Jerrod Denham currently serves as the VP of CMC at Ray Therapeutics, Inc., beginning in September 2023. Prior to this position, Denham was the VP of Technical Operations for Cell Therapy at Athenex from June 2022 to July 2023 and held the role of VP of Manufacturing & Site Lead at Resilience from April 2021 to June 2022, where Denham played a key role in developing cell and gene therapy manufacturing capabilities. Denham also served briefly as VP of Manufacturing & Site Lead at Ology Bioservices, Inc. before its acquisition by Resilience, and as Principal at Dark Horse Consulting Inc., providing expertise to over 70 clients in the biopharmaceutical sector. In earlier roles, Denham directed manufacturing sciences at StemCells, Inc., supervised process development at ViaCyte, Inc., and managed stem cell processing at Geron. Denham began a career in research at the University of California, Los Angeles, after earning a BS in Physiological Sciences from UCLA.